Farma Mondo Group and Stemline Therapeutics B.V. sign exclusive partnership to grant access to Elacestrant through Named Patient Supplies to patients in certain Countries where the product is not licensed or not commercially available.
Chiasso, Switzerland – Farma Mondo Group, a Swiss-based pharmaceutical group focused on providing market access and speciality distribution services through a unique infrastructure and geographical footprint across emerging and emerged markets, announced today the signing of an exclusive Global NPS agreement for granting access to patients to elacestrant, which is approved in the E.U. as a monotherapy indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.
Yaron Spigel, Group Chief Executive Officer of Farma Mondo, commented: We are excited to support Stemline Therapeutics to globally extend access to their novel therapy for patients with unmet medical needs. We are infinitely committed to the global patient communities to continue working for broader access to innovative therapeutic options.
About Farma Mondo Group
Farma Mondo is a fast-growing Swiss group dedicated to providing Biopharma, healthcare professionals and their patients around the world with greater access to medicines, and in the process increasing the value of a pharmaceutical product by extending and expanding its lifecycle. The Group offers high value market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to enable patient access in key Emerging Markets through a combined approach of Named Patient access and full commercialization.
